Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Nelson Hayes

Showing results (141-150 of 161) with videos related to

Pageof 17
Sort By:
Journal of Gastroenterology and Hepatology|January 3, 2020
Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy casesKana Daijo, Takashi Nakahara, Yuki Inagaki, et al.
Internal Medicine (Tokyo, Japan)|September 3, 2025
The Efficacy and Safety of Atezolizumab Plus Bevacizumab after Durvalumab Plus Tremelimumab for the Treatment of Hepatocellular CarcinomaShinsuke Uchikawa, Tomokazu Kawaoka, Aiko Tanaka, et al.
Cellular and Molecular Gastroenterology and Hepatology|February 18, 2017
Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid BiopsyAtsushi Ono, Akihiro Fujimoto, Yujiro Yamamoto, et al.
Therapeutic Advances in Medical Oncology|June 18, 2020
Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinibAtsushi Ono, Hiroshi Aikata, Masami Yamauchi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 27, 2016
Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis CKei Morio, Michio Imamura, Yoshiiku Kawakami, et al.
Plos One|August 11, 2017
The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapyYuko Nagaoki, Michio Imamura, Hiroshi Aikata, et al.
BMC Cancer|November 29, 2022
Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumorsYuki Yoshikawa, Michio Imamura, Masami Yamauchi, et al.
Communications Medicine|October 25, 2023
Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinomaMasami Yamauchi, Atsushi Ono, Kei Amioka, et al.
Plos One|December 31, 2013
HLA-DQB1*03 confers susceptibility to chronic hepatitis C in Japanese: a genome-wide association studyDaiki Miki, Hidenori Ochi, Atsushi Takahashi, et al.
Virology|September 22, 2018
Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytesMasataka Tsuge, Nobuhiko Hiraga, Yizhou Zhang, et al.
Pageof 17

Showing results (141-150 of 161) with videos related to

Sort By:
Pageof 17
Journal of Gastroenterology and Hepatology|January 3, 2020
Risk factors for histological progression of non-alcoholic steatohepatitis analyzed from repeated biopsy casesKana Daijo, Takashi Nakahara, Yuki Inagaki, et al.
Internal Medicine (Tokyo, Japan)|September 3, 2025
The Efficacy and Safety of Atezolizumab Plus Bevacizumab after Durvalumab Plus Tremelimumab for the Treatment of Hepatocellular CarcinomaShinsuke Uchikawa, Tomokazu Kawaoka, Aiko Tanaka, et al.
Cellular and Molecular Gastroenterology and Hepatology|February 18, 2017
Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid BiopsyAtsushi Ono, Akihiro Fujimoto, Yujiro Yamamoto, et al.
Therapeutic Advances in Medical Oncology|June 18, 2020
Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinibAtsushi Ono, Hiroshi Aikata, Masami Yamauchi, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|February 27, 2016
Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis CKei Morio, Michio Imamura, Yoshiiku Kawakami, et al.
Plos One|August 11, 2017
The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapyYuko Nagaoki, Michio Imamura, Hiroshi Aikata, et al.
BMC Cancer|November 29, 2022
Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumorsYuki Yoshikawa, Michio Imamura, Masami Yamauchi, et al.
Communications Medicine|October 25, 2023
Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinomaMasami Yamauchi, Atsushi Ono, Kei Amioka, et al.
Plos One|December 31, 2013
HLA-DQB1*03 confers susceptibility to chronic hepatitis C in Japanese: a genome-wide association studyDaiki Miki, Hidenori Ochi, Atsushi Takahashi, et al.
Virology|September 22, 2018
Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytesMasataka Tsuge, Nobuhiko Hiraga, Yizhou Zhang, et al.
Pageof 17